Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.
You may also be interested in...
Following Vyondys 53 rebuff, Sarepta CEO contends it would be "disrespectful" to release the complete response letter, while FDA contends that there is nothing stopping companies from publishing the letters.
Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.
Outgoing FDA commissioner said his direct contact with center directors helped agency advance policies and helped centers solve their problems.